Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
ONC has a shareholder filing a notice to sell 4,676 American Depositary Shares (ADS). The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value listed as
The ADS were acquired on 02/04/2026 through an exercise of stock options, paid in cash on the same date. The filing also lists recent Rule 10b5-1 sales for Chan Lee, including 996 ADS sold on
BeOne Medicines Ltd. insider Lee Chan Henry, SVP and General Counsel, reported option exercises and an automatic sale of American Depositary Shares (ADS). On January 7, 2026, Henry exercised three share options covering 2,626, 3,458 and 2,548 Ordinary Shares at exercise prices of
BeOne Medicines Ltd. reported that its President and Global Head of R&D received a large equity award in the form of restricted share units. On December 31, 2025, the executive acquired 427,895 ordinary shares at a stated price of $0, reflecting the vesting terms of these units rather than a cash purchase.
After this transaction, the executive beneficially owns 1,451,424 ordinary shares directly and 601,965 shares indirectly through Wang Holdings LLC. The filing also explains a separate RMB Shares Employee Participation Plan tied to the company’s STAR Market offering in China, under which the plan purchased 2,069,546 RMB Shares at an initial public offering price of RMB192.6 per share. The reporting person contributed RMB10 million to this plan and may have an indirect economic interest in some of these RMB Shares while disclaiming beneficial ownership except for any pecuniary interest.
BeOne Medicines Ltd. has fully repaid and terminated a major credit facility with China Merchants Bank Co., Ltd. The company used a portion of the borrowings from its previously disclosed Facilities Agreement, arranged with The Hongkong and Shanghai Banking Corporation Limited and other lenders, to pay off all outstanding amounts under the prior CMB Credit Facility.
As part of this repayment, all commitments by China Merchants Bank to extend further credit, as well as all guarantees and security interests granted by BeOne Medicines under the CMB Credit Facility, were terminated. The company incurred no termination penalties in connection with ending this facility.
BeOne Medicines Ltd. appointed Dr. Lai Wang as President, Global Head of Research and Development, effective January 1, 2026. In this expanded role, he will lead research and development as well as other functions, including business development and alliance management.
Dr. Wang, age 48, has led the Company’s R&D since April 2021 after joining in 2011, and previously served as Director of Research at Joyant Pharmaceuticals. His new compensation includes a $750,000 annual salary, an annual target bonus equal to 75% of base salary, and a one-time equity incentive of $10,000,000 in restricted share units vesting in four equal annual installments, with certain accelerated vesting rights under his employment agreement. The Company states there are no related-party or other arrangements connected to his appointment.
BeOne Medicines Ltd. chief executive officer and director reported sales of American Depositary Shares in mid-December 2025 under a pre-arranged Rule 10b5-1 trading plan.
The Form 4 discloses multiple sales of American Depositary Shares on 12/15/2025 and 12/16/2025 at weighted average prices listed in the report, with each American Depositary Share representing 13 ordinary shares. Following these transactions, the reporting person holds 0 American Depositary Shares directly but continues to beneficially own 5,141,041 ordinary shares directly and additional ordinary shares through various trusts and entities, with certain indirect interests expressly disclaimed as beneficial ownership.
BeOne Medicines Ltd. director reports option exercise and ADS sales. On 11/26/2025, the reporting director exercised a share option covering 34,151 ordinary shares at an exercise price of
ONC filed a Form 144 indicating that stockholder Xiaobin Wu plans to sell 3,991 shares of common stock through Morgan Stanley Smith Barney LLC on or about 11/17/2025, with an aggregate market value of $1,518,302.91. The shares are listed on NASDAQ, and the issuer reports 109,663,273 common shares outstanding.
The seller acquired 1,238 and 2,753 common shares through restricted stock vesting under a registered plan in June 2025. Over the past three months, the seller reported additional sales of 6,009 and 10,000 common shares, with gross proceeds of $2,286,659.45 and $3,560,160.50, respectively.
BeOne Medicines Ltd. (ONC) reported insider transactions by its President and COO. The reporting person sold 16,009 American Depositary Shares (ADS) on 11/12/2025 and 11/13/2025 at weighted average prices with trade ranges from $350.00 to $381.50, as detailed in the footnotes.
After these sales, the reporting person held 0 ADS directly. Beneficial ownership also includes 1,020,861 ordinary shares and 4,000 ADS held indirectly by spouse. Each ADS represents 13 ordinary shares. One footnote states that the ordinary share total includes 650 ordinary shares acquired under the company’s employee share purchase plan.
BeOne Medicines (ONC) reported insider activity by its SVP, General Counsel. On 11/12/2025, the officer exercised share options into 996 American Depositary Shares (ADS), which equals 12,948 Ordinary Shares (each ADS represents 13 Ordinary Shares), and sold 996 ADS pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
The ADS sales were executed at $348.75 (664 ADS) and $350 (332 ADS). Following these transactions, the reporting person beneficially owned 223,106 Ordinary Shares directly. The option exercises reflected exercise prices represented in Ordinary Shares of $14.96, $16.41, and $12.23, respectively.